Tocilizumab Prevents Progression of Early Systemic Sclerosis Associated Interstitial Lung Disease

OBJECTIVE: Tocilizumab has demonstrated lung function preservation in two randomized controlled trials in early systemic sclerosis (SSc). This effect has yet to be characterized in terms of quantitative radiographic lung involvement. In this post-hoc analysis, we assess tocilizumab’s impact on lung...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis Rheumatol
Main Authors: Roofeh, David, Lin, Celia J F, Goldin, Jonathan, Kim, Grace Hyun, Furst, Daniel E, Denton, Christopher P, Huang, Suiyuan, Khanna, Dinesh
Format: Artigo
Language:Inglês
Published: 2021
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8238790/
https://ncbi.nlm.nih.gov/pubmed/33538094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.41668
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items